Evidence map›Paper›PMID 29773845›Full record

ArticleScientific reports2018

AICAR inhibits NFκB DNA binding independently of AMPK to attenuate LPS-triggered inflammatory responses in human macrophages.

Johannes Kirchner, Bernhard Brüne, Dmitry Namgaladze

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Studying the Geroprotective Properties of YAP/TAZ Signaling Inhibitors onInternational journal of molecular sciences · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Metabolomic and transcriptional profiling reveals bioenergetic stress and activation of cell death and inflammatory pathwaysJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Johannes KirchnerInstitute of Biochemistry I, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany.
Bernhard BrüneInstitute of Biochemistry I, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany.
Dmitry NamgaladzeInstitute of Biochemistry I, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany. namgalad@biochem.uni-frankfurt.de.
Goethe University Frankfurt · DEFraunhofer Institute for Translational Medicine and Pharmacology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) is an established pharmacological activator of AMP-activated protein kinase (AMPK). Both, AICAR and AMPK were reported to attenuate inflammation. However, AICAR is known for many AMPK-independent effects, although the mechanisms remain incompletely understood. Here we report a potent suppression of lipopolysaccharide (LPS)-induced inflammatory gene expression by AICAR in primary human macrophages, which occurred independently of its conversion to AMPK-activating 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl monophosphate. Although AICAR did not interfere with activation of cytosolic signalling cascades and nuclear translocation of nuclear factor - κB (NFκB) by LPS, it prevented the recruitment of NFκB and RNA polymerase II to target gene promoters. AICAR also inhibited signal transducer and activator of transcription 3 (STAT3)-dependent induction of interleukin (IL) IL-6 and IL-10 targets, while leaving STAT6 and HIF1α-dependent gene expression in IL-4 and dimethyloxalylgylcine-treated macrophages intact. This points to a transcription factor-specific mode of action. Attenuated gene expression correlated with impaired NFκB and STAT3, but not HIF-binding in electrophoretic mobility shift assays in vitro. Conclusively, AICAR interferes with DNA binding of NFκB and STAT3 to modulate inflammatory responses.

Indexed as

Aminoimidazole CarboxamideAMP-Activated Protein KinasesGene Expression RegulationHumansLipopolysaccharidesMacrophagesNF-kappa BRibonucleotidesAICA ribonucleotideAminoimidazole CarboxamideAMP-Activated Protein KinasesLipopolysaccharidesNF-kappa BRibonucleotides

Identifiers

PMID29773845
PMCPMC5958102
OpenAlexW2806110370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.